Ovarian hyperstimulation syndrome as a cause of acute limb ischemia.

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic condition that can cause significant morbidity and mortality. Patients may present with a range of symptoms, including abdominal pain and distention, nausea, and vomiting that can rapidly progress to hemodynamic instability, renal failure, severe electrolyte derangements, thromboembolism, large-volume ascites, pleural effusion, and respiratory failure. We present a case of an 18-year-old woman who developed OHSS after egg donation with subsequent lower-extremity arterial thrombosis and compartment syndrome requiring fasciotomy and vascular intervention.

Thyroid storm obscured by acute asthma exacerbation and concurrent H1N1 influenza.

We present an uncommon case of H1N1 triggered thyroid storm in a patient with previously undiagnosed Grave's Disease. This case illustrates the challenges of diagnosing thyroid storm in the emergency department and the importance of including it in the differential when treating more common diagnoses that fail to respond to usual therapies. Thyroid storm is an endocrinologic emergency and requires prompt recognition and treatment.

Traumatic Pneumoperitoneum After Vaginal Intercourse.

Objectives: Pneumoperitoneum with peritonitis, although uncommon, is a serious injury encountered in the pediatric emergency department. Although the patients may often appear ill or toxic, they can have normal vital signs at initial presentation. Patients with such injury can present with a variety of complaints because of the nature of referred pain.

Refinement of anatomic indications for the Nellix System for endovascular aneurysm sealing based on 2-year outcomes from the EVAS FORWARD IDE trial.

Background: The Nellix System (Endologix, Inc, Irvine, Calif) for endovascular aneurysm sealing (EVAS) is a novel approach to abdominal aortic aneurysm treatment and conceptually different from endovascular aneurysm repair, whereby polymer is employed to fill and actively manage the abdominal aortic aneurysm sac. One-year safety and effectiveness results of the Nellix pivotal trial demonstrated encouraging outcomes with very low morbidity and mortality and high procedural and treatment success. Two-year imaging revealed a signal of migration, leading to a field safety notification issued by the manufacturer on October 21, 2016, and a dedicated root cause analysis, resulting in refinements to the instructions for use (IFU).

One-year pivotal trial outcomes of the Nellix system for endovascular aneurysm sealing.

Objective: The Nellix EndoVascular Aneurysm Sealing (EVAS) System (Endologix, Inc, Irvine, Calif) is a novel approach to abdominal aortic aneurysm (AAA) treatment whereby polymer is used to fill the AAA sac. We report 1-year results of the investigational device exemption pivotal trial.

Methods: Eligible patients were treated at 30 sites in the United States and Europe.

Motor Vehicle Collision Secondary to Ventricular Dysrhythmia: A Case Report of Brugada Syndrome.

Background: Brugada syndrome is a genetic disorder that increases an individual's risk for sudden cardiac death and ventricular dysrhythmias that was first described by the Brugada brothers in 1992. Brugada syndrome is characterized by an atypical electrocardiogram pattern that includes a bundle branch block and ST-segment elevation in the precordial leads.

Case Report: A 74-year-old man had a cardiac arrest at the time of a low-speed motor vehicle collision.

Extreme anemia (hemoglobin 1.8 g/dL) secondary to colon cancer.

We present the case of a 34-year-old man who presented to the emergency department with complaints of generalized fatigue and palpitations, with a heart rate of approximately 100 beats per minute and an orthostatic blood pressure of 80/30 mm Hg upon standing. A hemoglobin of 1.8 g/dL was discovered.

Mortality After Nontraumatic Major Amputation Among Patients With Diabetes and Peripheral Vascular Disease: A Systematic Review.

High mortality rates have been reported after major amputations of a lower limb secondary to diabetes and peripheral vascular disease. However, the mortality rates have varied across studies. A systematic review of the 5-year mortality after nontraumatic major amputations of the lower extremity was conducted.

Surgical management of carotid body tumors: a 15-year single institution experience employing an interdisciplinary approach.

Cervical paragangliomas are rare neoplasms that arise from extraadrenal paraganglia in close association with the cranial nerves and extracranial arterial system of the head and neck, and therefore surgical extirpation can be challenging. A retrospective study was conducted of all patients undergoing surgical excision of a cervical paraganglioma between 2000 and 2015. The demographic characteristics, clinical features, surgical approach, and outcomes were reviewed.

Results of the Nellix system investigational device exemption pivotal trial for endovascular aneurysm sealing.

Objective: The Nellix EndoVascular Aneurysm Sealing system (Endologix, Inc, Irvine, Calif) is a novel approach to abdominal aortic aneurysm (AAA) endovascular repair whereby biocompatible polymer is employed to exclude and to seal the AAA sac. We report 30-day results of the U.S.

The impact of foot ulceration and amputation on mortality in diabetic patients. I: From ulceration to death, a systematic review.

A great deal of emphasis, clinical and financial, is placed on limb salvage efforts in diabetic patients suffering from lower extremity ulceration. This is because of the impression that amputation in such patients may be a proximal cause of death. While amputation is certainly a negative clinical outcome, it is not entirely clear that it causes death.

Endovascular aortoiliac aneurysm repair: surgical progress through new treatment paradigms and innovative endograft design.

Effective treatment for patients with an abdominal aortic aneurysm (AAA) began more than 50 years ago through the development of prosthetic grafts, which were used to replace aneurysmal segments of diseased arteries. Open surgical repair of AAAs became the gold standard for treating this disease. In 1999, two device manufacturers received US Food and Drug Administration approval for their endovascular aneurysm repair (EVAR) devices to treat selected patients with AAA.

The management of chronic venous insufficiency with ulceration: the role of minimally invasive perforator interruption.

Background: The purpose of this study was to analyze the long-term outcomes associated with interruption of incompetent perforator veins (IPV) using minimally invasive techniques as adjunctive therapies in the management of patients with chronic venous insufficiency (CVI).

Methods: This is a retrospective review of a prospectively maintained venous database collected over 6 years (2005-2011). The study cohort included 64 patients with CVI stage C5 or C6 who underwent minimally invasive perforator interruption with subfascial endoscopic perforator surgery (SEPS) or radiofrequency ablation of IPV (RFA-IPV) as part of the management of their CVI.

Limitations of current EVAR endografts and potential solutions for their deficiencies.

All current endovascular aneurysm repair (EVAR) devices have defined limitations that prevent the endovascular therapist from using them to treat all forms of aortoiliac aneurysm disease. Short, angulated infrarenal aortic neck pathology, occlusive disease in iliac access arteries, need for preservation of important branch vessel arterial flow, endograft migration, and endoleak all represent major impediments for successful EVAR. Need for secondary intervention after EVAR in a significant number of patients has detracted from universal acceptance for this therapy.

Influence and critique of the PIVOTAL and the EVAR 2 Trials.

Management of a condition that has potentially life-threatening consequences may not lend itself effectively to the scrutiny of a randomized clinical trial when an observation or no treatment option is offered as part of the trial. This type of trial often experiences a significant rate of crossover of subjects from no treatment to treatment, and when results are analyzed on an intent-to-treat basis, they may fail to resolve the issue under study. These trials are frequently used as Level 1 medical evidence and the potential impact on clinical decision-making and reimbursement can be quite significant and long-lasting.

One year outcomes of the United States regulatory trial of the Endurant Stent Graft System.

Objective: To report the 1-year outcomes of the United States (US) regulatory trial of the Endurant Stent Graft System (Medtronic Vascular), a new device for the treatment of abdominal aortic aneurysms (AAA).

Methods: This was a prospective, single arm, multicenter trial conducted at 26 sites in the US. From April 2008 to May 2009, 150 patients with AAA were treated with the Endurant bifurcated stent graft.

Endovascular repair of a pancreatic allograft mycotic aneurysm: two-year follow-up.

Purpose: To describe midterm outcome of endovascular stent-graft repair of a mycotic aneurysm associated with a peripancreatic allograft abscess after transplantation.

Case Report: A 46-year-old woman underwent combined kidney and pancreas allograft transplantation under heavy immunosuppression. She developed a peripancreatic allograft abscess with associated mycotic aneurysm of the pancreatic allograft donor iliac artery 2 months after transplantation.

Economic and outcomes-based analysis of the care of symptomatic varicose veins.

Objective: Endoluminal treatment of symptomatic varicose veins (VV) reduces or eliminates inpatient hospital stays, lowers complication rates, and increases revenue for vein care centers adopting the technique. This study compares the outcomes and economics of two treatments for VV.

Methods: Since May 2007, endovenous radiofrequency ablation (RFA) of symptomatic VV has been performed at our institution.